The Effects of Pre-emptive Administration of Ketamine and norBNI on Pain Behavior, c-Fos, and Prodynorphin Protein Expression in the Rat Spinal Cord after Formalin-induced Pain Is Modulated by the DREAM Protein
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background:We investigated the effects of pre-emptive administration of ketamine and norBNI on pain behavior and the expression of DREAM, c-Fos, and prodynorphin proteins on the ipsilateral side of the rat spinal cord at 2 and 4 hours after formalin injection. Methods:Eighty-four male Sprague Dawley rats were divided into 4 major groups consisting of control rats (C) (n = 12), rats given only formalin injections (F) (n = 24), and rats treated with pre-emptive administration of either ketamine (K+F) (n = 24) or norBNI (N+F) (n = 24). The non-control groups were further divided into subgroups consisting of rats that were sacrificed at 2 and 4 hours (n = 12 for each group) after formalin injection. Pain behavior was recorded for 1 hour. After 2 and 4 hours, the rats were sacrificed and the spinal cords (L4−L5 sections) were removed for immunohistochemistry and Western blot analysis. Results:The pain behavior response was reduced in the K+F group compared to the other groups during the second phase of the formalin pain response. We detected an increase in the nuclear DREAM protein level in the K+F group at 2 and 4 hours and a transient decrease in the N+F group at 2 hours; however, it increased at 4 hours after injection. Fos-like immunoreactivity (FLI) and Prodynorphin-like immunoreactivity (PLI) neurons decreased in the K+F group but increased in the N+F group at 2 hours after injection. While FLI decreased, PLI increased in all groups at 4 hours after injection. Conclusions:We suggest that NMDA and kappa opioid receptors can modulate DREAM protein expression, which can affect pain behavior and protein transcriptional processes at 2 hours and bring about either harmful or protective effects at 4 hours after formalin injection. (Korean J Pain 2013; 26: 255-264)
Abstract
Background:We investigated the effects of pre-emptive administration of ketamine and norBNI on pain behavior and the expression of DREAM, c-Fos, and prodynorphin proteins on the ipsilateral side of the rat spinal cord at 2 and 4 hours after formalin injection. Methods:Eighty-four male Sprague Dawley rats were divided into 4 major groups consisting of control rats (C) (n = 12), rats given only formalin injections (F) (n = 24), and rats treated with pre-emptive administration of either ketamine (K+F) (n = 24) or norBNI (N+F) (n = 24). The non-control groups were further divided into subgroups consisting of rats that were sacrificed at 2 and 4 hours (n = 12 for each group) after formalin injection. Pain behavior was recorded for 1 hour. After 2 and 4 hours, the rats were sacrificed and the spinal cords (L4−L5 sections) were removed for immunohistochemistry and Western blot analysis. Results:The pain behavior response was reduced in the K+F group compared to the other groups during the second phase of the formalin pain response. We detected an increase in the nuclear DREAM protein level in the K+F group at 2 and 4 hours and a transient decrease in the N+F group at 2 hours; however, it increased at 4 hours after injection. Fos-like immunoreactivity (FLI) and Prodynorphin-like immunoreactivity (PLI) neurons decreased in the K+F group but increased in the N+F group at 2 hours after injection. While FLI decreased, PLI increased in all groups at 4 hours after injection. Conclusions:We suggest that NMDA and kappa opioid receptors can modulate DREAM protein expression, which can affect pain behavior and protein transcriptional processes at 2 hours and bring about either harmful or protective effects at 4 hours after formalin injection. (Korean J Pain 2013; 26: 255-264)
참고문헌 (36)
- Carrión AM, "DREAM is a Ca2+-regulated transcriptional repressor", Nature, 398, pp.80~84 (1999)
- Cheng HY, "DREAM is a critical transcriptional repressor for pain modulation", Cell, 108, pp.31~43 (2002)
- Lilliehook C, "Altered Abeta formation and long-term potentiation in a calsenilin knock-out", J Neurosci, 23, pp.9097~9106 (2003)
- Obara I, "Antagonists of the kappa-opioid receptor enhance allodynia in rats and mice after sciatic nerve ligation", Br J Pharmacol, 140, pp.538~546 (2003)
- Sevostianova N, "Analgesic effects of morphine and loperamide in the rat formalin test: interactions with NMDA receptor antagonists", Eur J Pharmacol, 525, pp.83~90 (2005)
- Snijdelaar DG, "Effects of pre-treatment with amantadine on morphine induced antinociception during second phase formalin responses in rats", Pain, 119, pp.159~167 (2005)
- Fukuda T, "The formalin test: effects of formalin concentration and short-term halothane inhalation", Reg Anesth Pain Med, 26, pp.407~413 (2001)
- Il-OkLee, "Effects of Different Concentrations of Formalin on Paw Edema and Pain Behaviors in Rats", Journal of Korean Medical Science, 17(1), pp.81~85 (2002), 대한의학회
- Myoung Joong Kim, "Antinociceptive Effects of Intraperitoneal and Intrathecal Vitamin E in the Rat Formalin Test", The Korean Journal of Pain, 25(4), pp.238~244 (2012), 대한통증학회
- Hayati AA, "Modulation of formalin-induced fos-like immunoreactivity in the spinal cord by swim stress-induced analgesia, morphine and ketamine", Ger Med Sci, 6, pp.Doc05~ (2008)
- Grossman A, "Opiate receptors: enkephalins and endorphins", Clin Endocrinol Metab, 12, pp.31~56 (1983)
- Horan P, "Extremely longlasting antagonistic actions of nor-binaltorphimine (nor-BNI) in the mouse tail-flick test", J Pharmacol Exp Ther, 260, pp.1237~1243 (1992)
- Spanagel R, "Evidence that nor-binaltorphimine can function as an antagonist at multiple opioid receptor subtypes", Eur J Pharmacol, 264, pp.157~162 (1994)
- Endoh T, "Nor-binaltorphimine: a potent and selective kappa-opioid receptor antagonist with long-lasting activity in vivo", Arch Int Pharmacodyn Ther, 316, pp.30~42 (1992)
- Broadbear JH, "Differential effects of systemically administered nor-binaltorphimine (nor-BNI) on kappa-opioid agonists in the mouse writhing assay", Psychopharmacology (Berl), 115, pp.311~319 (1994)
- Dubuisson D, "The formalin test: a quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats", Pain, 4, pp.161~174 (1977)
- Hao S, "Sevoflurane suppresses noxious stimulus-evoked expression of Fos-like immunoreactivity in the rat spinal cord via activation of endogenous opioid systems", Life Sci, 71, pp.571~580 (2002)
- Molander C, "The cytoarchitectonic organization of the spinal cord in the rat. I. The lower thoracic and lumbosacral cord", J Comp Neurol, 230, pp.133~141 (1984)
- Towbin H, Staehelin T, Gordon J, "Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications", Proc Natl Acad Sci U S A, 76, pp.4350~4354 (1979)
- Berrino L, "Antinociceptive effect in mice of intraperitoneal N-methyl-D-aspartate receptor antagonists in the formalin test", Eur J Pain, 7, pp.131~137 (2003)
- Ossipov MH, "Opioid antagonists and antisera to endogenous opioids increase the nociceptive response to formalin: demonstration of an opioid kappa and delta inhibitory tone", J Pharmacol Exp Ther, 277, pp.784~788 (1996)
- Coderre TJ, "The formalin test: a validation of the weighted-scores method of behavioural pain rating", Pain, 54, pp.43~50 (1993)
- Wu HE, "Roles of endogenous opioid peptides in modulation of nocifensive response to formalin", J Pharmacol Exp Ther, 300, pp.647~654 (2002)
- Choi SS, "Possible antinociceptive mechanisms of opioid receptor antagonists in the mouse formalin test", Pharmacol Biochem Behav, 75, pp.447~457 (2003)
- Ikeda H, "Synaptic amplifier of inflammatory pain in the spinal dorsal horn", Science, 312, pp.1659~1662 (2006)
- Ledo F, "DREAM-alphaCREM interaction via leucine-charged domains derepresses downstream regulatory element-dependent transcription", Mol Cell Biol, 20, pp.9120~9126 (2000)
- Zaidi NF, "Intracellular calcium modulates the nuclear translocation of calsenilin", J Neurochem, 89, pp.593~601 (2004)
- Zhang Y, "Distribution of downstream regulatory element antagonist modulator (DREAM) in rat spinal cord and upregulation of its expression during inflammatory pain", Neurochem Res, 32, pp.1592~1599 (2007)
- Long I, "Increases in mRNA and DREAM protein expression in the rat spinal cord after formalin induced pain", Neurochem Res, 36, pp.533~539 (2011)
- Edling Y, "Glutamate activates c-fos in glial cells via a novel mechanism involving the glutamate receptor subtype mGlu5 and the transcriptional repressor DREAM", Glia, 55, pp.328~340 (2007)
- Chavira-Suárez E, "D-Serine", Nmethyl- D-aspartate receptor signaling decreases DNAbinding activity of the transcriptional repressor DREAM in Müller glia from the retina, 2008, pp.432, 121~126
- Coderre TJ, "The role of NMDA receptor-operated calcium channels in persistent nociception after formalininduced tissue injury", J Neurosci, 12, pp.3671~3675 (1992)
- JinuLee, "Regulation of DREAM Expression by Group I mGluR", The Korean Journal of Physiology & Pharmacology, 15(2), pp.95~100 (2011), 대한약리학회
- Hunt SP, "Induction of c-fos-like protein in spinal cord neurons following sensory stimulation", Nature, 328, pp.632~634 (1987)
- Ji RR, "ERK MAP kinase activation in superficial spinal cord neurons induces prodynorphin and NK-1 upregulation and contributes to persistent inflammatory pain hypersensitivity", J Neurosci, 22, pp.478~485 (2002)
- Zhang Y, "The DREAM protein negatively regulates the NMDA receptor through interaction with the NR1 subunit", J Neurosci, 30, pp.7575~7586 (2010)